Targeting angiogenesis -- a novel mode in cancer chemoprevention

Area of Science:

• Oncology
• Molecular Biology
• Preventive Medicine

Background:

• Cancer development is a multistage process, offering opportunities for early intervention.
• The angiogenic switch, a critical step in tumor growth, is increasingly recognized as an early event in carcinogenesis.
• Chemoprevention aims to prevent or delay cancer by targeting these early stages before clinical symptoms arise.

Purpose of the Study:

• To explore the role of angiogenesis in cancer chemoprevention.
• To evaluate the potential of antiangiogenic agents as cancer preventive strategies.
• To discuss the mechanisms of action for current chemopreventive agents and their impact on angiogenesis.

Main Methods:

• Review of current scientific literature on cancer chemoprevention and angiogenesis.
• Analysis of clinical trial data for chemopreventive agents targeting angiogenesis.
• Examination of the mechanisms by which nonsteroidal anti-inflammatories, tamoxifen, and retinoids may exert protective effects.

Main Results:

• Evidence suggests that the angiogenic switch is an early event in carcinogenesis.
• Several chemopreventive agents, including NSAIDs, tamoxifen, and retinoids, demonstrate antiangiogenic properties.
• These antiangiogenic effects likely contribute to the protective role of these agents in cancer prevention.

Conclusions:

• Targeting angiogenesis represents a promising strategy for cancer chemoprevention.
• Specific antiangiogenic agents, used alone or in combination, hold significant potential for future cancer prevention therapies.
• Further research into antiangiogenic agents could open new possibilities in the field of cancer chemoprevention.